Literature DB >> 17849096

Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance.

M Adiels1, J Westerbacka, A Soro-Paavonen, A M Häkkinen, S Vehkavaara, M J Caslake, C Packard, S O Olofsson, H Yki-Järvinen, M R Taskinen, J Borén.   

Abstract

AIMS/HYPOTHESIS: Overproduction of VLDL(1) seems to be the central pathophysiological feature of the dyslipidaemia associated with type 2 diabetes. We explored the relationship between liver fat and suppression of VLDL(1) production by insulin in participants with a broad range of liver fat content.
METHODS: A multicompartmental model was used to determine the kinetic parameters of apolipoprotein B and TG in VLDL(1) and VLDL(2) after a bolus of [(2)H(3)]leucine and [(2)H(5)]glycerol during a hyperinsulinaemic-euglycaemic clamp in 20 male participants: eight with type 2 diabetes and 12 control volunteers. The participants were divided into two groups with low or high liver fat. All participants with diabetes were in the high liver-fat group.
RESULTS: The results showed a rapid drop in VLDL(1)-apolipoprotein B and -triacylglycerol secretion in participants with low liver fat during the insulin infusion. In contrast, participants with high liver fat showed no significant change in VLDL(1) secretion. The VLDL(1) suppression following insulin infusion correlated with the suppression of NEFA, and the ability of insulin to suppress the plasma NEFA was impaired in participants with high liver fat. A novel finding was an inverse response between VLDL(1) and VLDL(2) secretion in participants with low liver fat: VLDL(1) secretion decreased acutely after insulin infusion whereas VLDL(2) secretion increased. CONCLUSIONS/
INTERPRETATION: Insulin downregulates VLDL(1) secretion and increases VLDL(2) secretion in participants with low liver fat but fails to suppress VLDL(1) secretion in participants with high liver fat, resulting in overproduction of VLDL(1). Thus, liver fat is associated with lack of VLDL(1) suppression in response to insulin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17849096     DOI: 10.1007/s00125-007-0790-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  45 in total

1.  Adipocyte differentiation-related protein promotes fatty acid storage in cytosolic triglycerides and inhibits secretion of very low-density lipoproteins.

Authors:  Björn Magnusson; Lennart Asp; Pontus Boström; Michel Ruiz; Pia Stillemark-Billton; Daniel Lindén; Jan Borén; Sven-Olof Olofsson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-04-20       Impact factor: 8.311

2.  Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects.

Authors:  R Malmström; C J Packard; M Caslake; D Bedford; P Stewart; H Yki-Järvinen; J Shepherd; M R Taskinen
Journal:  Diabetes       Date:  1998-05       Impact factor: 9.461

3.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

4.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Authors:  Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

Review 5.  Review: The role of insulin resistance in nonalcoholic fatty liver disease.

Authors:  Kristina M Utzschneider; Steven E Kahn
Journal:  J Clin Endocrinol Metab       Date:  2006-09-12       Impact factor: 5.958

6.  Regulation of microsomal triglyceride transfer protein gene by insulin in HepG2 cells: roles of MAPKerk and MAPKp38.

Authors:  Wo-Shing Au; Hsiang-fu Kung; Marie C Lin
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

Review 7.  Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis.

Authors:  S-O Olofsson; J Borèn
Journal:  J Intern Med       Date:  2005-11       Impact factor: 8.989

8.  Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content.

Authors:  Mirja Tiikkainen; Robert Bergholm; Satu Vehkavaara; Aila Rissanen; Anna-Maija Häkkinen; Marjo Tamminen; Kari Teramo; Hannele Yki-Järvinen
Journal:  Diabetes       Date:  2003-03       Impact factor: 9.461

9.  Dietary fat content modifies liver fat in overweight nondiabetic subjects.

Authors:  Jukka Westerbacka; Katriina Lammi; Anna-Maija Häkkinen; Aila Rissanen; Irma Salminen; Antti Aro; Hannele Yki-Järvinen
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

Review 10.  Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity.

Authors:  Shirya Rashid; Takehiko Watanabe; Taro Sakaue; Gary F Lewis
Journal:  Clin Biochem       Date:  2003-09       Impact factor: 3.281

View more
  61 in total

Review 1.  Hepatic ABCA1 and VLDL triglyceride production.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta       Date:  2011-10-06

Review 2.  Carotenoids and non-alcoholic fatty liver disease.

Authors:  Bahiddin Yilmaz; Kazim Sahin; Hande Bilen; Ibrahim H Bahcecioglu; Birdal Bilir; Sara Ashraf; Karim J Halazun; Omer Kucuk
Journal:  Hepatobiliary Surg Nutr       Date:  2015-06       Impact factor: 7.293

3.  Suppression of Type-II Diabetes with Dyslipidemia and Nephropathy by Peels of Musa cavendish Fruit.

Authors:  Vijay Navghare; Shashikant Dhawale
Journal:  Indian J Clin Biochem       Date:  2016-02-03

Review 4.  The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease.

Authors:  Sven M Francque
Journal:  Eur Cardiol       Date:  2014-07

Review 5.  Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.

Authors:  Sandra J Hamilton; Gerald F Watts
Journal:  Rev Diabet Stud       Date:  2013-08-10

6.  Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study.

Authors:  Carlos Lorenzo; Sara Hartnett; Anthony J Hanley; Marian J Rewers; Lynne E Wagenknecht; Andrew J Karter; Steven M Haffner
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

7.  Sodium acetate improves disrupted glucoregulation and hepatic triglyceride content in insulin-resistant female rats: involvement of adenosine deaminase and dipeptidyl peptidase-4 activities.

Authors:  Tolulope Eniola Omolekulo; Olugbenga Samuel Michael; Lawrence Aderemi Olatunji
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-02       Impact factor: 3.000

8.  Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids.

Authors:  Mirjana Pavlic; Changting Xiao; Linda Szeto; Bruce W Patterson; Gary F Lewis
Journal:  Diabetes       Date:  2009-12-22       Impact factor: 9.461

9.  Associations of age with serum insulin, proinsulin and the proinsulin-to-insulin ratio: a cross-sectional study.

Authors:  Bente Bryhni; Egil Arnesen; Trond G Jenssen
Journal:  BMC Endocr Disord       Date:  2010-12-16       Impact factor: 2.763

Review 10.  Nutritional systems biology modeling: from molecular mechanisms to physiology.

Authors:  Albert A de Graaf; Andreas P Freidig; Baukje De Roos; Neema Jamshidi; Matthias Heinemann; Johan A C Rullmann; Kevin D Hall; Martin Adiels; Ben van Ommen
Journal:  PLoS Comput Biol       Date:  2009-11-26       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.